The Food and Drug Administration yesterday said that it will temporarily forgo action against 503A compounding pharmacies that provide to hospitals certain compounded drugs without patient-specific prescriptions.

The agency’s temporary policy outlines specific criteria that pharmacies and hospitals must meet in addition to some conditions established in section 503A of the Federal Food, Drug, and Cosmetic Act.

While the agency recently provided additional guidance for 503B outsourcing facilities, it acknowledged that the flexibilities provided might not be sufficient to meet urgent needs. FDA says this new policy is intended to remain in effect for no longer than the duration of the COVID-19 public health emergency and will be modified as circumstances evolve.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services this week released updated fact sheets for hospitals and other types of Medicare and Medicaid providers…
Headline
Health care providers who received Provider Relief Fund and/or American Rescue Plan Rural payments exceeding $10,000 total between July 1 and Dec. 31, 2021,…
Headline
The House last night voted 220-210 to pass legislation (H.R.382) that would immediately terminate the COVID-19 public health emergency, and 227-203 to pass…
Headline
As the Congressional Telehealth Caucus considers updates to legislation that would permanently remove all geographic restrictions on Medicare telehealth…
Headline
The Biden Administration plans to end on May 11 the COVID-19 national and public health emergencies declared in 2020, according to a policy statement …
Headline
The Centers for Medicare & Medicaid Services Friday released additional guidance on changes to the Medicaid continuous enrollment requirement under…